Genmab — Marts 2014
-
dlbcl - relapsed mostly, en del refractory
-
hovedsageligt behandlet med rituxan+chop
-
continue to be optimistic there is a difference btw arms
-
dvs arzerra lammetæsker guldstandarden i direkte kamp med rituxan!!!!!!!!!!!!!!!!
-
masser abstracts til ASCO. Sådan
-
for asco - multiple abstracts submitted
-
både mono og revlimid
-
revilimid + differet dosage studies
-
både på mm og andre indikationer indenfor hæmatologi
-
davani? hvor er han fra?
-
jeffries mener jeg JV - men er ikke sikker
-
ok - tak
-
spørg dog til pipelinen man!!!
-
ja - jeg vil høre mere, det er det spændende er
-
200 mio usd remainin på arzerra - 100 udvikling 100 salg
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind